Recent Updates
Recently added Catalysts

Gammagard Liquid

Phase 3

Multiple Myeloma | Monoclonal antibody | Oncology |Takeda Pharmaceutical Company Limited|Last Updated: Sep 9, 2026

Target and mechanism

ModalityMonoclonal antibody

Also known as IGI, 10%

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLEDDMC
Total Trials1
Total Enrollment183

FDA Designations

No designations recorded

Clinical trial landscape

Gammagard Liquid · 1 trial · 2 indications

Phase 3 1
NCT06980480A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple MyelomaMultiple Myeloma
RECRUITING183 Analytics
PHASE3RECRUITING
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Multiple MyelomaUnlock trial analytics

Study Endpoints

Primary Endpoints

Time To the First Serious Infection
Up to 12 months

Secondary Endpoints

Number of Participants With at Least 1 Serious Infection
Up to 12 months
Annualized Rate of Days on Antibiotics for Treatment of Bacterial Infections
Up to 12 months
Annualized Rate of Bacterial Infections
Up to 12 months
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposePREVENTION

Treatment Arms

ArmTypeDescription
Primary Infection Prophylaxis: IGI, 10%EXPERIMENTALParticipants randomized to primary infection prophylaxis will receive a 400 milligrams per kilogram (mg/kg) dose of IGI, 10% in accordance with the standard of care (SOC), intravenously (IV) every 3 or 4 weeks within 3 days after randomization up to 12 months.
Secondary Infection Prophylaxis: IGI, 10%ACTIVE_COMPARATORParticipants randomized to secondary infection prophylaxis will receive a 400 mg/kg dose of IGI, 10% in accordance with the SOC, IV every 3 or 4 weeks only after experiencing at least one serious infection, as determined by the investigator, for the remainder of the 12 months observational period.

Interventions

NameTypeDescription
IGI, 10%BIOLOGICALIGI, 10% IV infusion.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites56

Inclusion Criteria: 1. The participants must have a documented diagnosis of Multiple Myeloma (MM) according to the guidelines by the International Myeloma Working Group (IMWG) before enrollment. 2. Participant who recently started teclistamab monotherapy within the first 8 weeks of their planned tr...

Countries:United StatesAustraliaAustriaBrazilCanadaCzechiaDenmarkGreeceHungaryItalyNetherlandsNorwayPolandRomaniaSpainUnited Kingdom
Unlock Eligibility Criteria

Competitive Landscape -Multiple Myeloma 221 trials

Top 20 of 25 competitors

CompanyTickerTrialsLead PhaseDrugs
AbbVie, Inc.ABBV16PHASE3Pomalidomide, Dexamethasone, Venetoclax
Bristol-Myers Squibb CompanyBMY18PHASE3Iberdomide, Lenalidomide
Takeda Pharmaceutical Co. Ltd. Sponsored ADRTAK5PHASE3IGI, 10%
GSK plc Sponsored ADRGSK17PHASE3Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib
Johnson & JohnsonJNJ28PHASE3Talquetamab, Pomalidomide, Teclistamab, Elotuzumab, Dexamethasone
Regeneron Pharmaceuticals, Inc.REGN11PHASE3Linvoseltamab, Carfilzomib, Daratumumab, Dexamethasone, Pomalidomide
Pfizer Inc.PFE11PHASE3Elranatamab, Lenalidomide
Sanofi SA Sponsored ADRSNY17PHASE3Isatuximab, Dexamethasone, Pomalidomide, Montelukast, Paracetamol/ Acetaminophen
AstraZeneca PLCAZN5PHASE3AZD0120, Daratumumab, Carfilzomib, Dexamethasone, Bortezomib
Gilead Sciences, Inc.GILD3PHASE3Anitocabtagene Autoleucel, Cyclophosphamide, Fludarabine, Pomalidomide, Bortezomib
Karyopharm Therapeutics, Inc.KPTI6PHASE3Selinexor, Elotuzumab, Pomalidomide, Dexamethasone
Grifols, S.A. Sponsored ADR Class BGRFS1PHASE3Xembify
BioLineRX Ltd. Sponsored ADRBLRX1PHASE3BL-8040/kg, G-CSF
C4 Therapeutics, Inc.CCCC3PHASE2Cemsidomide, Dexamethasone
Cellectar Biosciences, Inc.CLRB1PHASE2Iopofosine I 131 single dose, Iopofosine I 131 fractionated dose
GeoVax Labs, Inc.GOVX1PHASE2COVID-19 Vaccine, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1
Autolus Therapeutics Plc Sponsored ADRAUTL1PHASE2AUTO CAR T cell therapy
Incyte CorporationINCY2PHASE1Ruxolitinib, Lenalidomide, Methylprednisolone
Moderna, Inc.MRNA2PHASE1mRNA-2808
BeOne Medicines Ltd. Sponsored ADRONC1PHASE1Sonrotoclax, Dexamethasone, Carfilzomib, Daratumumab, Pomalidomide
Unlock Competitive Intelligence

Recent Changes (Last 90 Days)

LOWSep 9, 2026NCT06980480lastUpdatePostDate: changed
LOWSep 9, 2026NCT06980480lastUpdatePostDate: changed
LOWAug 7, 2026NCT06980480lastUpdatePostDate: changed
LOWAug 7, 2026NCT06980480lastUpdatePostDate: changed
LOWJul 17, 2026NCT06980480lastUpdatePostDate: changed
LOWJul 17, 2026NCT06980480lastUpdatePostDate: changed